Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 5Terminated 4Unknown 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 14Dermatologic 11Breast 6Gynecologic 5Thoracic 4Head & Neck 4Tumor-Agnostic 3Gastrointestinal 3NET 2Lymphoid 2Endocrine 2Other solid neoplasm 1Myeloid 1CNS 1

Conditions

Uveal Melanoma 1Primary Myelofibrosis 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 58Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 43acalabrutinib 42Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × avelumab × Lymphoid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT03244176 2024-07-30

AvR-CHOP

Austin Health

Phase EARLY_PHASE1 Active not recruiting
28 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡